This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): tafluprost, MK-2452, Taflotan (EU), Tapros (Japan), DE-085, Saflutan, DE-118 (unit-dose)
Description: DE-085 (tafluprost) is a preservative-free formulation of a prostanoid with prostaglandin F(FP)-receptor agonist activity. Tafluprost is an isopropyl ester and is rapidly hydrolyzed by corneal esterases to become the biologically active metabolite, the free acid of tafluprost. Tafluprost is highly selective and potent agonist for FP-receptors. Its chemical structure differs from that of the other previously available prostanoids: instead of a hydroxyl group at the carbon 15 position it hastwo fluorine atoms. The compound is being developed as a treatment for elevated intraocular pressure in glaucoma and ocular hypertension. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes, possibly through cell-shape changes, cytoskeletal alterations, or compactionof the extracellular matrix.
Deal Structure: DE-085 was co-developed with Asahi Glass. Santen conducts pharmaceutical and clinical development, while Asahi Glass is responsible for manufacturing development of the active pharmaceutical ingredient.
Santen and Merck
In April 2009, Merck and Santen Pharmaceutical announced a worldwide licensing agreement for tafluprost. Under the terms of the agreement, Merck will pay an undisclosed fee as well as milestones and royalty payments based on future sales of tafluprost (both preserved and preservative-free formulations) in exchange for exclusive commercial rights to tafluprost in Western Europe (excluding Germany), North America, South America and Africa. Santen will retain commercial rights to tafluprost in most countries in Eastern Europe, Northern Europe and Asia Pacific, including Japan. Merck will provide promotion support to Santen in Germany and Poland. If tafluprost is approved in the U.S., Santen has an option to co-promote it there.
In May 2014, Merck...See full deal structure in Biomedtracker
Partners: Santen Pharmaceutical Co., Ltd. Merck & Co., Inc.
Pink Sheet New Molecular Entities Approved In 2012
Additional information available to subscribers only: